Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acorda Positions Ampyra For Large Market Of Post-Stroke Deficits

This article was originally published in The Pink Sheet Daily

Executive Summary

Acorda plans to move Ampyra to Phase III for treating post-stroke deficits, after reporting positive Phase II results. The company also reported a signal from a small proof-of-concept study in cerebral palsy, but next steps are unclear in that indication.

You may also be interested in...



Earnings Briefs: Mylan, AbbVie, Vertex, Novo Nordisk, Gilead, Acorda

Mylan sticks with Abbott deal, confident that it will be a successful tax inversion, while AbbVie rules out similar deals after walking away from Shire upon deciding recent tax policy changes rule out its own inversion play. Other updates from the third-quarter earnings calls, in brief.

Business News, In Brief

Novo Nordisk and Allergan both report setbacks during their respective first quarter earnings calls. Meanwhile, Valeant and Actavis avoid speculation about a potential merger, and other Q1 happenings.

The Long Road To Approval: Acorda Experience With Ampyra Shows Success Of Novel Analysis Plan

Acorda Therapeutics' challenges in seeking approval for its oral therapy Ampyra to improve walking ability in patients with multiple sclerosis were greater than most from the start: it was a novel drug for a first-of-its-kind claim – and the drug yielded variable efficacy on an unproven endpoint. What seems to have made the difference is the creative analysis plan that Acorda came up with.

Topics

Related Companies

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel